Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes

Who May Qualify: - Patients diagnosed with type 2 diabetes mellitus - Adults aged 60 years or older - Patients with a Mini-Mental State Examination (MMSE) score between 24 and 28 within the past 3 months Who Should NOT Join This Trial: - Patients with type 1 diabetes mellitus, diabetic ketoacidosis, or diabetic coma or precoma - Patients with poorly controlled blood glucose (HbA1c \> 10.0%) - Patients with an MMSE score below 24 - Patients diagnosed with dementia (e.g., Alzheimer's disease) - Patients with suspected cognitive impairment due to other causes - Patients requiring antiplatelet or anticoagulant therapy other than the investigational product - Patients with thyroid dysfunction requiring treatment (i.e., abnormal TSH levels) - Patients with severe depression - Patients with severe infections, recent surgery (perioperative status), or major trauma - Patients with pituitary or adrenal insufficiency - Patients with other medical conditions requiring hospitalization - Patients with a history of alcohol or drug abuse within 1 year prior to screening - Patients with a history of taking medications that may affect cognitive function within 3 months prior to screening - Patients deemed by the investigator to be otherwise unsuitable for study participation Always talk to your doctor about whether this trial is right for you.